Risk of Lymphoma Increased in People Taking Thiopurines for IBD

A meta-analysis of 18 cohort studies shows that people with inflammatory bowel disease (IBD) who take thiopurines are at a nearly six-fold increased risk of developing lymphoma compared to the general population.

Specifically, Dr. David Kotlyar of the National Cancer Institute and colleagues found that these patients had a 5.7-fold greater incidence of lymphoma over the general population.

This increased risk only applied to people who took thiopurines (azathioprine or 6-mercaptopurine) for at least one year. Risk appeared to drop back down to that of the general population after patients stop taking thiopurines. This, according to researchers, suggests that the mechanism of carcinogensis is not DNA damage, but rather suppression of the immune system by this class of drugs.

"It is important to emphasize that although the relative risks of lymphoma in active users are moderate, there remains a very low absolute risk of lymphoma for any given patient," wrote researchers. "For patients of all ages and genders, the risk of lymphoma needs to be weighed against the potential benefits of therapy. Further work is needed to understand how this trade-off of potential benefit and harm varies by age, particularly in the era of combination immunosuppression therapy."

The team reported their findings in the journal Clinical Gastroenterology and Hepatology.

Source: Oncologypractice.com

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap